IXC

0.00%

7.1¢ invex therapeutics ltd

Questions to ask Tom in relation to recent announcement dated 27.09.2021, page-19

First 19 Last

Share
Profile

Follow
edb11

190 Posts.

22

28/09/21

16:27

Post #: 56410530
Share

Originally posted by JabraD: ↑

Ok so what we have so far is the following update 4.18PM 28/09/2021:

-------------------------------------

Hi Tom,

Hope you are well.

Ive had discussions with a group of investors and instead of bombarding you with questions of a similar nature we have decided to compile a list of questions from all of us for you to hopefully asisst us with (we will post the answers on Hotcopper so all investors apart of forming this list get there answers satisfied).

Questions:

About Announcement

1.Why would you give notice of a conference call within 30 minutes of the conference call commencing? Why not announce something like that on Friday?

2.Why didn’t dr Baldwin or Loveridge participate in the conference? When will we get a chance to be able to ask them questions directly?

About Drug

3.If Presendin has been dropped, what protection against off-label use of generics does Invex have?
Is it only orphan drug designation?

4.Can you contrast the expected PK for Peptron's sustained Exenatide vs. Byetta vs. Daily Presendin or Exenatide vs. Bydureonvs. Daily Presendin

5. Why is Invex comfortable in proceeding straight to a P3 without repeating the P2 with Peptron's formulation?

6.What exactly has been licensed in/out and to whom (i.e., by how much have we cut potential profits globally by using Peptron's SR-formulation); for what cost (whether it be financial or otherwise); what are the limitations to each party during and post P3.
7. What has the FDA/EMA seen of PT320? Have they seen any of the pharmacokinetics or tolerability studies? Is the data package ready to go or will it need to be generated? How confident is Invex that the regulators would deem the current preclinical studies for PT320 to be acceptable?

8. Do you think that the preclinical and clinical data from Peptron about PT320 will change the FDA's mind on the recommended primary endpoint for the phase III trial for Presendin?

Probably give it to 12PM tonight, any other questions?

Expand

Great stuff putting this together. Very interested to see the responses.

IXC Price at posting: 72.0¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

LAM

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

SBW

Shekel Brainweigh investor presentation webinar – the future of retail automation

OCC

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

BIT

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

RMX

Red Mountain Mining: record gold prices, two projects, two greenstone belts

QML

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

CBA breaks trading record on strong day for Aussie financials

As Nvidia cools, we're looking to Aussie AI

PRU

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

There are more pages in this discussion • 80 more messages in this thread...

First 19 Last

Add IXC (ASX) to my watchlist

(20min delay)
Last 7.1¢		Change 0.000(0.00%)		Mkt cap ! $5.335M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
1	28320	7.0¢

Sellers (Offers)

Price($)	Vol.	No.
7.2¢	22452	2

View Market Depth

No.	Vol.	Price($)
1	28320	0.070
1	84879	0.067
1	100000	0.066
1	100000	0.065
2	166666	0.060

Price($)	Vol.	No.
0.072	22452	2
0.080	5000	1
0.085	8805	1
0.090	126146	1
0.095	100000	1

Last trade - 16.12pm 06/09/2024 (20 minute delay)

IXC (ASX) Chart

Day chart unavailable

Questions to ask Tom in relation to recent announcement dated 27.09.2021, page-19

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

Shekel Brainweigh investor presentation webinar – the future of retail automation

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

CBA breaks trading record on strong day for Aussie financials

As Nvidia cools, we're looking to Aussie AI

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Questions to ask Tom in relation to recent announcement dated 27.09.2021, page-19

Top Stories

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

Shekel Brainweigh investor presentation webinar – the future of retail automation

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

CBA breaks trading record on strong day for Aussie financials

As Nvidia cools, we're looking to Aussie AI

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News